tisagenlecleucel
| Brand name | Kymriah |
|---|---|
| Active ingredient | tisagenlecleucel |
| Strength | 0.6 to 6.0 x 10^8 CAR-POSITIVE VIABLE T CELLS |
| Dosage form | Injection |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | August 2017 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.